- |||||||||| Biomarker, Trial completion, Enrollment change: Evaluation of Molecular Markers in Adrenal Tumors (clinicaltrials.gov) - Dec 7, 2017
P=N/A, N=71, Completed, Completed --> Terminated; Slow/insufficient accrual Recruiting --> Completed | N=500 --> 71
- |||||||||| Enrollment change, Trial termination, Trial primary completion date, Metastases: Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer (clinicaltrials.gov) - Sep 29, 2017
P2, N=6, Terminated, Recruiting --> Completed | Trial primary completion date: Feb 2019 --> Nov 2016 N=40 --> 6 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Jul 2011; Slow enrollment
- |||||||||| nevanimibe (ATR-101) / Millendo Therap
Trial primary completion date, Metastases: Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) - Feb 7, 2017 P1, N=78, Recruiting, N=40 --> 6 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Jul 2011; Slow enrollment Trial primary completion date: Feb 2017 --> Feb 2019
- |||||||||| Enrollment change, Trial primary completion date, Metastases: Possible New Therapy for Advanced Cancer (clinicaltrials.gov) - Nov 19, 2014
P1/2, N=9, Terminated, Trial primary completion date: Jun 2015 --> Dec 2015 N=36 --> 9 | Trial primary completion date: Dec 2015 --> Mar 2014
- |||||||||| Trial termination, Metastases: Possible New Therapy for Advanced Cancer (clinicaltrials.gov) - Nov 18, 2014
P1/2, N=36, Terminated, N=36 --> 9 | Trial primary completion date: Dec 2015 --> Mar 2014 Recruiting --> Terminated; Business decision by the sponsor during Phase 1.
- |||||||||| nevanimibe (ATR-101) / Millendo Therap
Enrollment change, Trial primary completion date, Metastases: Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov) - Aug 21, 2014 P1, N=59, Recruiting, Recruiting --> Terminated; Business decision by the sponsor during Phase 1. N=21 --> 59 | Trial primary completion date: Aug 2014 --> Jun 2015
|